United Therapeutics (NASDAQ:UTHR) has been given a $106.00 target price by investment analysts at Cowen in a note issued to investors on Wednesday. The firm currently has a “hold” rating on the biotechnology company’s stock. Cowen’s price target indicates a potential downside of 7.46% from the stock’s current price.
Several other analysts have also recently commented on the company. Zacks Investment Research cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 22nd. BidaskClub upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 17th. Standpoint Research upgraded United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, October 12th. Wedbush set a $253.00 target price on United Therapeutics and gave the stock a “buy” rating in a report on Thursday, September 27th. Finally, TheStreet cut United Therapeutics from a “b” rating to a “c+” rating in a report on Thursday, September 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $138.29.
NASDAQ:UTHR traded down $8.12 during trading hours on Wednesday, reaching $114.55. The company had a trading volume of 13,903 shares, compared to its average volume of 328,121. United Therapeutics has a one year low of $100.57 and a one year high of $152.55. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of 10.52, a price-to-earnings-growth ratio of 26.56 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35.
Several institutional investors and hedge funds have recently modified their holdings of UTHR. Legacy Financial Advisors Inc. acquired a new position in shares of United Therapeutics during the second quarter valued at $107,000. Sun Life Financial INC acquired a new position in shares of United Therapeutics during the second quarter valued at $198,000. Balasa Dinverno & Foltz LLC acquired a new position in shares of United Therapeutics during the third quarter valued at $260,000. Fox Run Management L.L.C. acquired a new position in shares of United Therapeutics during the second quarter valued at $269,000. Finally, IFM Investors Pty Ltd acquired a new position in shares of United Therapeutics during the third quarter valued at $301,000. 94.62% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: Understanding Average Daily Trade Volume
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.